Research Programme: hepatocellular carcinoma vaccines - HepaVac consortiumAlternative Names: Cancer Vaccine - HEPAVAC; Hepatocellular carcinoma vaccine - HapaVaC; HepaVac-101 vaccine
Latest Information Update: 22 Jul 2016
At a glance
- Originator Fondazione IRCCS Istituto Nazionale dei Tumori; immatics biotechnologies GmbH; University of Insurbia; University of Tubingen
- Developer Fondazione IRCCS Istituto Nazionale dei Tumori; immatics biotechnologies GmbH; University of Tubingen
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hepatocellular carcinoma